Gene Biotherapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income.
Profit Margin
| 2013 | 109.2K | -8.91M | -8163.27% |
|---|---|---|---|
| 2014 | 0 | -5.50M | |
| 2015 | 0 | -3.69M | |
| 2016 | 0 | -2.91M | |
| 2017 | 0 | -1.89M | |
| 2018 | 0 | -434.88K | |
| 2019 | 0 | 866.67K | |
| 2020 | 0 | -575.29K | |
| 2021 | 0 | 0 | |
| 2022 | 0 | 0 |
CRXM Income Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 109.2K |
Cost of revenue | 0 | 0 | 1.81K | 58.17K | 0 | 66.08K | 0 | 9.88K | 0 | 69.16K |
Gross profit | 0 | 0 | -1.81K | -58.17K | 0 | -66.08K | 0 | -9.88K | 0 | 40.04K |
Operating exp. | ||||||||||
Research and development | 0 | 0 | 217.58K | 243.45K | 255.39K | 344.97K | 641.57K | 361.48K | 640.42K | 2.03M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 0 | 0 | 1.26M | 837.00K | 1.16M | 2.12M | 2.84M | 3.11M | 3.57M | 6.94M |
Operating income | 0 | 0 | -1.26M | -837.00K | -513.23K | -2.07M | -2.84M | -3.11M | -3.57M | -6.90M |
Other income (expenses), net | 0 | 0 | 610.63K | 1.61M | 650K | -20.21K | -172.82K | -582.59K | -1.92M | -554 |
Income before tax | 0 | 0 | -651.55K | 779.12K | -552.74K | -2.09M | -3.01M | -3.69M | -5.50M | -6.90M |
Income tax expense | 0 | 0 | -76.25K | -43.76K | -767.86K | -252.36K | -95.58K | 500K | 1.83M | 2.00M |
Net income | 0 | 0 | -575.29K | 866.67K | -434.88K | -1.89M | -2.91M | -3.69M | -5.50M | -8.91M |
Earnings per share | ||||||||||
Basic EPS | 0 | 0 | -0.02 | 0.05 | -0.03 | -0.13 | -0.22 | -0.29 | -0.5 | -1.27 |
Diluted EPS | 0 | 0 | -0.02 | 0.05 | -0.03 | -0.13 | -0.22 | -0.29 | -0.5 | -1.27 |
| Data source | Data source | Data source | Data source | Data source | Data source |